Top

Published in:

01-04-2012 | Bladder and Urothelial Cancer (A Sagalowsky, Section Editor)

Biomolecular Predictors of Urothelial Cancer Behavior and Treatment Outcomes

Authors: Michael Rink, Eugene K. Cha, David Green, Jens Hansen, Brian D. Robinson, Yair Lotan, Arthur I. Sagalowsky, Felix K. Chun, Pierre I. Karakiewicz, Margit Fisch, Douglas S. Scherr, Shahrokh F. Shariat

Published in: Current Urology Reports | Issue 2/2012

Abstract

Urothelial carcinoma of the urinary bladder (UCB) is a highly heterogeneous malignancy that causes significant morbidity and mortality. Despite advances in surgical and medical treatment, there has been no change in mortality in UCB over the past decades. Standard pathological features (stage, grade, nodal status) provide only limited information regarding biological potential and clinical behavior. Molecular biomarkers may shed light on important mechanisms of pathogenesis, provide useful additional prognostic information, and serve as targets for therapy. This review summarizes recent advances and the most promising UCB tissue and blood biomarkers of the past few years. We discuss the predictive and prognostic value of biomarkers at different stages of UCB. There is no doubt that a panel of biomarkers will eventually improve our clinical decision-making with regard to treatment and follow-up.

Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300. doi:10.3322/caac.20073.PubMedCrossRef

Karakiewicz PI, Shariat SF, Palapattu GS, Gilad AE, Lotan Y, Rogers CG, et al. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. J Urol. 2006;176(4 Pt 1):1354–61. discussion 61-2.PubMedCrossRef

Shariat SF, Karakiewicz PI, Palapattu GS, Amiel GE, Lotan Y, Rogers CG, et al. Nomograms provide improved accuracy for predicting survival after radical cystectomy. Clin Cancer Res. 2006;12(22):6663–76.PubMedCrossRef

Bochner BH, Kattan MW, Vora KC. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol. 2006;24(24):3967–72.PubMedCrossRef

Rink M, Shariat SF. Can we apply nomograms derived in the United States to European patients? Yes, We Can! Eur Urol. 2011(Epub ahead of print).

Barbieri CE, Lotan Y, Lee RK, Sonpavde G, Karakiewicz PI, Robinson B, et al. Tissue-based molecular markers for bladder cancer. Minerva Urol Nefrol. 2010;62(3):241–58.PubMed

Matsushita K, Cha EK, Matsumoto K, Baba S, Chromecki TF, Fajkovic H et al. Immunohistochemical biomarkers for bladder cancer prognosis. Int J Urol. 2011(Epub ahead of print).

Shariat SF, Lotan Y, Vickers A, Karakiewicz PI, Schmitz-Dräger BJ, Goebell PJ, et al. Statistical consideration for clinical biomarker research in bladder cancer. Urol Oncol. 2010;28(4):389–400. doi:10.1016/j.urolonc.2010.02.011.PubMedCrossRef

Kim YK, Kim WJ. Epigenetic markers as promising prognosticators for bladder cancer. Int J Urol. 2009;16(1):17–22. doi:10.1111/j.1442-2042.2008.02143.x.PubMedCrossRef

10.

Shariat SF, Karakiewicz PI, Ashfaq R, Lerner SP, Palapattu GS, Cote RJ, et al. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer. 2008;112(2):315–25. doi:10.1002/cncr.23162.PubMedCrossRef

11.

Shariat SF, Karam JA, Lerner SP. Molecular markers in bladder cancer. Curr Opin Urol. 2008;18(1):1–8. doi:10.1097/MOU.0b013e3282f1c5c1.PubMedCrossRef

12.

Shariat SF, Tilki D. Bladder cancer: nomogram aids clinical decision making after radical cystectomy. Nat Rev Urol. 2010;7(4):182–4.PubMedCrossRef

13.

Vrooman OP, Witjes JA. Molecular markers for detection, surveillance and prognostication of bladder cancer. Int J Urol. 2009;16(3):234–43. doi:10.1111/j.1442-2042.2008.02225.x.PubMedCrossRef

14.

Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408(6810):307–10. doi:10.1038/35042675.PubMedCrossRef

15.

Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen SC, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med. 1994;331(19):1259–64.PubMedCrossRef

16.

Grossman HB, Liebert M, Antelo M, Dinney CP, Hu SX, Palmer JL, et al. p53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res. 1998;4(4):829–34.PubMed

17.

Shariat SF, Tokunaga H, Zhou J, Kim J, Ayala GE, Benedict WF, et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol. 2004;22(6):1014–24. doi:10.1200/jco.2004.03.118.PubMedCrossRef

18.

Stein JP, Ginsberg DA, Grossfeld GD, Chatterjee SJ, Esrig D, Dickinson MG, et al. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst. 1998;90(14):1072–9.PubMedCrossRef

19.

Dalbagni G, Presti J, Reuter V, Fair WR, Cordon-Cardo C. Genetic alterations in bladder cancer. Lancet. 1993;342(8869):469–71.PubMedCrossRef

20.

Knowles MA, Elder PA, Williamson M, Cairns JP, Shaw ME, Law MG. Allelotype of human bladder cancer. Cancer Res. 1994;54(2):531–8.PubMed

21.

Chatterjee SJ, Datar R, Youssefzadeh D, George B, Goebell PJ, Stein JP, et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol. 2004;22(6):1007–13. doi:10.1200/jco.2004.05.174.PubMedCrossRef

22.

Malats N, Bustos A, Nascimento CM, Fernandez F, Rivas M, Puente D, et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol. 2005;6(9):678–86. doi:10.1016/s1470-2045(05)70315-6.PubMedCrossRef

23.

Shariat SF, Lotan Y, Karakiewicz PI, Ashfaq R, Isbarn H, Fradet Y, et al. p53 predictive value for pT1-2 N0 disease at radical cystectomy. J Urol. 2009;182(3):907–13. doi:10.1016/j.juro.2009.05.024.PubMedCrossRef

24.

Shariat SF, Zlotta AR, Ashfaq R, Sagalowsky AI, Lotan Y. Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Mod Pathol. 2007;20(4):445–59. doi:10.1038/modpathol.3800757.PubMedCrossRef

25.

Shariat SF, Bolenz C, Karakiewicz PI, Fradet Y, Ashfaq R, Bastian PJ, et al. p53 expression in patients with advanced urothelial cancer of the urinary bladder. BJU Int. 2010;105(4):489–95. doi:10.1111/j.1464-410X.2009.08742.x.PubMedCrossRef

26.

•• Shariat SF, Chade DC, Karakiewicz PI, Ashfaq R, Isbarn H, Fradet Y et al. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J Urol. 2010;183(1):68-75. doi:10.1016/j.juro.2009.08.115. This study demonstrates the importance of using a combination of molecular markers for molecular staging, prognostication, and prediction of response to therapy. While status of individual molecular cell-cycle markers did not add sufficient value to outcome prediction in patients with advanced UCB, a combination of four markers was able to significantly improve prognostications.

27.

Shariat SF, Bolenz C, Godoy G, Fradet Y, Ashfaq R, Karakiewicz PI et al. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy. J Urol. 2009;182(1):78-84; discussion doi:10.1016/j.juro.2009.02.125.

28.

• Goebell PJ, Groshen SG, Schmitz-Dräger BJ, (ISBC) IS-IoBC. p53 immunohistochemistry in bladder cancer--a new approach to an old question. Urol Oncol. 2010;28(4):377-88. doi:10.1016/j.urolonc.2010.03.021. This large study comprising 3,421 patients demonstrates the value of p53 immunohistochemistry in prognostication of UCB >pT1. The results of this trial demonstrate the relevance of sufficient study size, provide a basis to define suitable patient populations, and allow an estimation of an adequate size of study cohorts for prospective trials.

29.

Dalbagni G, Parekh DJ, Ben-Porat L, Potenzoni M, Herr HW, Reuter VE. Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder. BJU Int. 2007;99(2):281–5. doi:10.1111/j.1464-410X.2006.06624.x.PubMedCrossRef

30.

Esuvaranathan K, Chiong E, Thamboo TP, Chan YH, Kamaraj R, Mahendran R, et al. Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha. Cancer. 2007;109(6):1097–105. doi:10.1002/cncr.22503.PubMedCrossRef

31.

Moonen PM, van Balken-Ory B, Kiemeney LA, Schalken JA, Witjes JA. Prognostic value of p53 for high risk superficial bladder cancer with long-term followup. J Urol. 2007;177(1):80–3. doi:10.1016/j.juro.2006.08.110.PubMedCrossRef

32.

Cormio L, Tolve I, Annese P, Saracino A, Zamparese R, Sanguedolce F, et al. Altered p53 and pRb expression is predictive of response to BCG treatment in T1G3 bladder cancer. Anticancer Res. 2009;29(10):4201–4.PubMed

33.

Oh JJ, Ji SH, Choi DK, Gong IH, Kim TH, Park DS. A six-week course of bacillus Calmette-Guerin prophylaxis is insufficient to prevent tumor recurrence in nonmuscle invasive bladder cancer with strong-positive expression of p53. Oncology. 2010;79(5–6):440–6.PubMedCrossRef

34.

• Park J, Song C, Shin E, Hong JH, Kim CS, Ahn H. Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy? Urol Oncol. 2011. This is one of only few studies failing to show an influence of seven different biomarkers on prognostication in 61 pT1G3 UCB patients with a primary BCG treatment. This study is an important example of the difficulties in evaluating biomarkers in UCB.

35.

•• Stadler WM, Lerner SP, Groshen S, Stein JP, Shi SR, Raghavan D et al. Phase III Study of Molecularly Targeted Adjuvant Therapy in Locally Advanced Urothelial Cancer of the Bladder Based on p53 Status. J Clin Oncol. 2011. This is the first study reporting a prospective randomized controlled trial assessing the impact of p53 on outcomes of pT1/T2/N0M0 UCB treated with adjuvant chemotherapy. The study demonstrated no difference in disease outcome or benefit of chemotherapy according to the biomarker status.

36.

Margulis V, Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. Clin Cancer Res. 2006;12(24):7369–73.PubMedCrossRef

37.

•• Margulis V, Lotan Y, Karakiewicz PI, Fradet Y, Ashfaq R, Capitanio U et al. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. J Natl Cancer Inst. 2009;101(2):114-9. doi:10.1093/jnci/djn451. In this large study of 713 patients treated with RC, Ki-67 labeling index was independently associated with aggressive pathological features and worse disease outcome. This marker holds the potential for a better patient stratification for perioperative chemotherapy.

38.

Behnsawy HM, Miyake H, Abdalla MA, Sayed MA, Ahmed AE, Fujisawa M. Expression of cell cycle-associated proteins in non-muscle-invasive bladder cancer: Correlation with intravesical recurrence following transurethral resection. Urol Oncol. 2009.

39.

Margulis V, Lotan Y, Shariat SF. Survivin: a promising biomarker for detection and prognosis of bladder cancer. World J Urol. 2008;26(1):59–65. doi:10.1007/s00345-007-0219-y.PubMedCrossRef

40.

Arai M, Sasaki A, Saito N, Nakazato Y. Immunohistochemical analysis of cleaved caspase-3 detects high level of apoptosis frequently in diffuse large B-cell lymphomas of the central nervous system. Pathol Int. 2005;55(3):122–9. doi:10.1111/j.1440-1827.2005.01808.x.PubMedCrossRef

41.

Karam JA, Lotan Y, Karakiewicz PI, Ashfaq R, Sagalowsky AI, Roehrborn CG, et al. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol. 2007;8(2):128–36. doi:10.1016/S1470-2045(07)70002-5.PubMedCrossRef

42.

Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene. 2003;22(53):8581–9. doi:10.1038/sj.onc.1207113.PubMedCrossRef

43.

Schultz IJ, Kiemeney LA, Karthaus HF, Witjes JA, Willems JL, Swinkels DW, et al. Survivin mRNA copy number in bladder washings predicts tumor recurrence in patients with superficial urothelial cell carcinomas. Clin Chem. 2004;50(8):1425–8. doi:10.1373/clinchem.2004.032003.PubMedCrossRef

44.

Shariat SF, Casella R, Khoddami SM, Hernandez G, Sulser T, Gasser TC, et al. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol. 2004;171(2 Pt 1):626–30. doi:10.1097/01.ju.0000107826.78479.90.PubMedCrossRef

45.

Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Alterieri DC. Urine detection of survivin and diagnosis of bladder cancer. JAMA. 2001;285(3):324–8.PubMedCrossRef

46.

Shariat SF, Ashfaq R, Karakiewicz PI, Saeedi O, Sagalowsky AI, Lotan Y. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer. 2007;109(6):1106–13. doi:10.1002/cncr.22521.PubMedCrossRef

47.

•• Shariat SF, Karakiewicz PI, Godoy G, Karam JA, Ashfaq R, Fradet Y et al. Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study. Clin Cancer Res. 2009;15(22):7012-9. doi:10.1158/1078-0432.ccr-08-2554. This large external validation study demonstrates the value of survivin expression for an improved prediction of cancer recurrence and survival in patients with pT1-3N0M0 UCB.

48.

Salz W, Eisenberg D, Plescia J, Garlick DS, Weiss RM, Wu XR, et al. A survivin gene signature predicts aggressive tumor behavior. Cancer Res. 2005;65(9):3531–4. doi:10.1158/0008-5472.can-04-4284.PubMedCrossRef

49.

Shariat SF, Youssef RF, Gupta A, Chade DC, Karakiewicz PI, Isbarn H, et al. Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers. J Urol. 2010;183(5):1744–50. doi:10.1016/j.juro.2010.01.018.PubMedCrossRef

50.

Das K, Zhao Y, Sugiono M, Lau W, Tan PH, Cheng C. Differential expression of vascular endothelial growth factor165b in transitional cell carcinoma of the bladder. Urol Oncol. 2007;25(4):317–21.PubMedCrossRef

51.

Herrmann E, Eltze E, Bierer S, Kopke T, Gorge T, Neumann J, et al. VEGF-C, VEGF-D and Flt-4 in transitional bladder cancer: relationships to clinicopathological parameters and long-term survival. Anticancer Res. 2007;27(5A):3127–33.PubMed

52.

Miyata Y, Kanda S, Ohba K, Nomata K, Hayashida Y, Eguchi J, et al. Lymphangiogenesis and angiogenesis in bladder cancer: prognostic implications and regulation by vascular endothelial growth factors-A, -C, and -D. Clin Cancer Res. 2006;12(3 Pt 1):800–6. doi:10.1158/1078-0432.ccr-05-1284.PubMedCrossRef

53.

Zu X, Tang Z, Li Y, Gao N, Ding J, Qi L. Vascular endothelial growth factor-C expression in bladder transitional cell cancer and its relationship to lymph node metastasis. BJU Int. 2006;98(5):1090–3. doi:10.1111/j.1464-410X.2006.06446.x.PubMedCrossRef

54.

Elfiky AA, Rosenberg JE. Targeting angiogenesis in bladder cancer. Curr Oncol Rep. 2009;11(3):244–9.PubMedCrossRef

55.

Mitra AP, Cote RJ. Molecular pathogenesis and diagnostics of bladder cancer. Annu Rev Pathol. 2009;4:251–85.PubMedCrossRef

56.

Knowles MA. Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target. World J Urol. 2007;25(6):581–93. doi:10.1007/s00345-007-0213-4.PubMedCrossRef

57.

van Rhijn BW, Zuiverloon TC, Vis AN, Radvanyi F, van Leenders GJ, Ooms BC, et al. Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur Urol. 2010;58(3):433–41.PubMedCrossRef

58.

Fajkovic H, Halpern JA, Cha EK, Bahadori A, Chromecki TF, Karakiewicz PI, et al. Impact of gender on bladder cancer incidence, staging, and prognosis. World J Urol. 2011;29(4):457–63.PubMedCrossRef

59.

Kaufmann M, Pusztai L. Use of standard markers and incorporation of molecular markers into breast cancer therapy: Consensus recommendations from an International Expert Panel. Cancer. 2011;117(8):1575–82.PubMedCrossRef

60.

Jimenez RE, Hussain M, Bianco Jr FJ, Vaishampayan U, Tabazcka P, Sakr WA, et al. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res. 2001;7(8):2440–7.PubMed

61.

Kassouf W, Black PC, Tuziak T, Bondaruk J, Lee S, Brown GA, et al. Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. J Urol. 2008;179(1):353–8. doi:10.1016/j.juro.2007.08.087.PubMedCrossRef

62.

Kruger S, Weitsch G, Buttner H, Matthiensen A, Bohmer T, Marquardt T, et al. HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications. Int J Cancer. 2002;102(5):514–8. doi:10.1002/ijc.10731.PubMedCrossRef

63.

Lae M, Couturier J, Oudard S, Radvanyi F, Beuzeboc P, Vieillefond A. Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann Oncol. 2010;21(4):815–9.PubMedCrossRef

64.

•• Fleischmann A, Rotzer D, Seiler R, Studer UE, Thalmann GN. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. Eur Urol. 2011;60(2):350-7. According to the results of this study, a targeted anti-HER2 therapy might have a greater potential in patients with metastatic disease than in patients with localized UCB. Furthermore, it is important to notice that HER2 expression is higher in metastatic sites and, therefore, analysis of primary tumor specimens might offer only an invalid picture of HER2 status.

65.

Bolenz C, Shariat SF, Karakiewicz PI, Ashfaq R, Ho R, Sagalowsky AI, et al. Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder. BJU Int. 2010;106(8):1216–22. doi:10.1111/j.1464-410X.2009.09190.x.PubMedCrossRef

66.

Boorjian S, Ugras S, Mongan NP, Gudas LJ, You X, Tickoo SK, et al. Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer. Urology. 2004;64(2):383–8. doi:10.1016/j.urology.2004.03.025.PubMedCrossRef

67.

• Tuygun C, Kankaya D, Imamoglu A, Sertcelik A, Zengin K, Oktay M et al. Sex-specific hormone receptors in urothelial carcinomas of the human urinary bladder: a comparative analysis of clinicopathological features and survival outcomes according to receptor expression. Urol Oncol. 2011;29(1):43-51. doi:10.1016/j.urolonc.2009.01.033. Only few studies investigated the value of sex hormonal receptors with respect to gender differences in UCB outcomes. This study investigated altered marker level of the androgen and estrogen-β receptor.

68.

Mir C, Shariat SF, van der Kwast TH, Ashfaq R, Lotan Y, Evans A, et al. Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study. BJU Int. 2011;108(1):24–30.PubMedCrossRef

69.

Bolenz C, Lotan Y, Ashfaq R, Shariat SF. Estrogen and progesterone hormonal receptor expression in urothelial carcinoma of the bladder. Eur Urol. 2009;56(6):1093–5. doi:10.1016/j.eururo.2009.06.032.PubMedCrossRef

70.

Shen SS, Smith CL, Hsieh JT, Yu J, Kim IY, Jian W, et al. Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue. Cancer. 2006;106(12):2610–6. doi:10.1002/cncr.21945.PubMedCrossRef

71.

Shariat SF, Karakiewicz PI, Ashfaq R, Isbarn H, Fradet Y, Bastian PJ, et al. Combination of cell cycle regulating bio-markers improves prognosis in patients with organ-confined urothelial carcinoma at radical cystectomy. J Urol. 2008;179(4):578.CrossRef

72.

Shariat SF, Kim J, Nguyen C, Wheeler TM, Lerner SP, Slawin KM. Correlation of preoperative levels of IGF-I and IGFBP-3 with pathologic parameters and clinical outcome in patients with bladder cancer. Urology. 2003;61(2):359–64.PubMedCrossRef

73.

Byrne RR, Shariat SF, Brown R, Kattan MW, Morton Jr RA, Wheeler TM, et al. E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. J Urol. 2001;165(5):1473–9.PubMedCrossRef

74.

Shariat SF, Monoski MA, Andrews B, Wheeler TM, Lerner SP, Slawin KM. Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. Urology. 2003;61(5):1053–8.PubMedCrossRef

75.

Andrews B, Shariat SF, Kim J-H, Wheeler TM, Slawin KM, Lerner SP. Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer. J Urol. 2002;167(3):1475–81.PubMedCrossRef

76.

Kim JH, Shariat SF, Kim IY, Menesses-Diaz A, Tokunaga H, Wheeler TM, et al. Predictive value of expression of transforming growth factor-beta(1) and its receptors in transitional cell carcinoma of the urinary bladder. Cancer. 2001;92(6):1475–83.PubMedCrossRef

77.

Shariat SF, Kim JH, Andrews B, Kattan MW, Wheeler TM, Kim IY, et al. Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma. Cancer. 2001;92(12):2985–92.PubMedCrossRef

78.

Castillejo A, Rothman N, Murta-Nascimento C, Malats N, Garcia-Closas M, Gomez-Martinez A, et al. TGFB1 and TGFBR1 polymorphic variants in relationship to bladder cancer risk and prognosis. Int J Cancer. 2009;124(3):608–13.PubMedCrossRef

79.

Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem. 1999;274(31):21491–4.PubMedCrossRef

80.

Cornelius LA, Nehring LC, Harding E, Bolanowski M, Welgus HG, Kobayashi DK, et al. Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol. 1998;161(12):6845–52.PubMed

81.

Ito T-K, Ishii G, Saito S, Yano K, Hoshino A, Suzuki T, et al. Degradation of soluble VEGF receptor-1 by MMP-7 allows VEGF access to endothelial cells. Blood. 2009;113(10):2363–9. doi:10.1182/blood-2008-08-172742.PubMedCrossRef

82.

Guan K-P, Ye H-Y, Yan Z, Wang Y, Hou S-K. Serum levels of endostatin and matrix metalloproteinase-9 associated with high stage and grade primary transitional cell carcinoma of the bladder. Urology. 2003;61(4):719–23.PubMedCrossRef

83.

Vasala K, Pääkkö P, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 immunoreactive protein as a prognostic marker in bladder cancer. Urology. 2003;62(5):952–7.PubMedCrossRef

84.

•• Svatek RS, Shah JB, Xing J, Chang D, Lin J, Mcconkey DJ et al. A multiplexed, particle-based flow cytometric assay identified plasma matrix metalloproteinase-7 to be associated with cancer-related death among patients with bladder cancer. Cancer. 2010;116(19):4513-9. doi:10.1002/cncr.25401. This study suggests that MMP-7 can help stratify patients for neoadjuvant or adjuvant treatment. Plasma levels of MMP-7 were significantly associated with cancer-specific survival.

85.

Szarvas T, Becker M, Vom Dorp F, Gethmann C, Tötsch M, Bánkfalvi A, et al. Matrix metalloproteinase-7 as a marker of metastasis and predictor of poor survival in bladder cancer. Cancer Sci. 2010;101(5):1300–8. doi:10.1111/j.1349-7006.2010.01506.x.PubMedCrossRef

86.

Szarvas T, Singer BB, Becker M, Vom Dorp F, Jager T, Szendroi A, et al. Urinary matrix metalloproteinase-7 level is associated with the presence of metastasis in bladder cancer. BJU Int. 2011;107(7):1069–73.PubMedCrossRef

87.

Szarvas T, Jager T, Becker M, Tschirdewahn S, Niedworok C, Kovalszky I, et al. Validation of circulating MMP-7 level as an independent prognostic marker of poor survival in urinary bladder cancer. Pathol Oncol Res. 2011;17(2):325–32.PubMedCrossRef

88.

Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351(8):781–91.PubMedCrossRef

89.

de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14(19):6302–9.PubMedCrossRef

90.

Msaouel P, Koutsilieris M. Diagnostic value of circulating tumor cell detection in bladder and urothelial cancer: systematic review and meta-analysis. BMC Cancer. 2011;11(1):336.PubMedCrossRef

91.

Nezos A, Msaouel P, Pissimissis N, Lembessis P, Sourla A, Armakolas A, et al. Methods of detection of circulating melanoma cells: a comparative overview. Cancer Treat Rev. 2010;37(4):284–90.PubMedCrossRef

92.

Gallagher DJ, Milowsky MI, Ishill N, Trout A, Boyle MG, Riches J, et al. Detection of circulating tumor cells in patients with urothelial cancer. Ann Oncol. 2009;20(2):305–8.PubMedCrossRef

93.

Gradilone A, Petracca A, Nicolazzo C, Gianni W, Cortesi E, Naso G, et al. Prognostic significance of survivin-expressing circulating tumour cells in T1G3 bladder cancer. BJU Int. 2010;106(5):710–5.PubMedCrossRef

94.

Guzzo TJ, McNeil BK, Bivalacqua TJ, Elliott DJ, Sokoll LJ, Schoenberg MP. The presence of circulating tumor cells does not predict extravesical disease in bladder cancer patients prior to radical cystectomy. Urol Oncol. 2009.

95.

• Rink M, Chun FK, Minner S, Friedrich M, Mauermann O, Heinzer H et al. Detection of circulating tumour cells in peripheral blood of patients with advanced non-metastatic bladder cancer. BJU Int. 2011;107(10):1668-75. This is the first study demonstrating an association of immunomagnetically captured CTC in the peripheral blood of patients with nonmetastatic UCB and worse cancer-specific outcomes.

96.

Mitra AP, Lin H, Datar RH, Cote RJ. Molecular biology of bladder cancer: prognostic and clinical implications. Clin Genitourin Cancer. 2006;5(1):67–77.PubMedCrossRef

Title: Biomolecular Predictors of Urothelial Cancer Behavior and Treatment Outcomes
Authors: Michael Rink
Eugene K. Cha
David Green
Jens Hansen
Brian D. Robinson
Yair Lotan
Arthur I. Sagalowsky
Felix K. Chun
Pierre I. Karakiewicz
Margit Fisch
Douglas S. Scherr
Shahrokh F. Shariat
Publication date: 01-04-2012
Publisher: Current Science Inc.
Published in: Current Urology Reports / Issue 2/2012
Print ISSN: 1527-2737
Electronic ISSN: 1534-6285
DOI: https://doi.org/10.1007/s11934-012-0237-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Biomolecular Predictors of Urothelial Cancer Behavior and Treatment Outcomes

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2012

Recent Advances in Treatment of Advanced Urothelial Carcinoma

Radical Prostatectomy as Primary Treatment of High-risk Prostate Cancer

Restaging Transurethral Resection of Bladder Tumor for High-risk Stage Ta and T1 Bladder Cancer

Active Surveillance for Favorable-risk Prostate Cancer: Background, Patient Selection, Triggers for Intervention, and Outcomes

Therapeutic Options for Advanced Prostate Cancer: 2011 Update

Focal Therapy of Prostate Cancer: Evidence-based Analysis for Modern Selection Criteria